Metformin is a common treatment for controlling high blood sugar in patients with type 2 diabetes. However, due to safety considerations, the current formulations of metformin are often not prescribed to type 2 diabetes patients who also have advanced chronic kidney disease. The purpose of this study is to test an investigational formulation of metformin called Metformin Delayed Release (DR). It is designed to be absorbed in the small intestine rather than the stomach. This study will evaluate whether the DR formulation could reduce systemic exposure to metformin and lead to fewer side effects for type 2 diabetes patients with chronic kidney disease.